TGTX Q1 2025 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$121M+90.4% YoY

Gross Profit

$105M87.1% margin

Operating Income

$9M7.1% margin

Net Income

$5M4.2% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+11.7%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$657M

Total Liabilities

$419M

Stockholders' Equity

$237M

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$121M	$63M	+90.4%
Gross Profit	$105M	$58M	+81.7%
Operating Income	$9M	-$9M	+193.0%
Net Income	$5M	-$11M	+147.3%

Revenue Segments

Product

$120M99%

Royalty

$605,0001%

Other Revenue

$558,0000%

License Revenue

$38,0000%